With ICI, the response rate to first or second-line anti-PD1 in BRAF-mutated or wild-type (WT) melanomas ranged from 42% [8] to 45% [9,10,11], with a median PFS of 8.4 to 9.7 [8] and 6.9 months [9,10,11] with pembrolizumab and nivolumab, respectively. Here, BRAF is linked to melanoma.